End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57,900 KRW | -2.85% | -2.53% | -19.58% |
May. 03 | SK Bioscience's Attributable Loss Narrows in Q1 | MT |
Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.58% | 3.37B | B- | ||
-3.17% | 89.69B | A- | ||
+2.50% | 41.34B | A- | ||
-12.01% | 33.72B | B- | ||
+62.74% | 26.11B | A | ||
-19.79% | 14.63B | C | ||
-8.58% | 12.84B | B- | ||
-12.34% | 11.66B | D+ | ||
-43.92% | 11.52B | B | ||
+4.27% | 8.92B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A302440 Stock
- Ratings SK bioscience Co.,Ltd.